ImmuPharma (LON:IMM) Trading 28.8% Higher – Here’s What Happened

ImmuPharma plc (LON:IMMGet Free Report)’s share price traded up 28.8% on Saturday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). 44,749,293 shares were traded during trading, an increase of 451% from the average session volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Price Performance

The stock has a market cap of £69.86 million, a PE ratio of -1,570.67 and a beta of 1.53. The stock has a 50-day moving average price of GBX 3.12 and a two-hundred day moving average price of GBX 2.91.

ImmuPharma (LON:IMMGet Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Equities research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzorâ„¢), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

See Also

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.